Liposomal encapsulation of nutrients
Bioavailability is a major challenge when administering medicines or nutrients. How well does the body absorb the active substance? Does it actually reach its intended destination? And, if so, how much of it gets there? Compared with oral intake, intravenous administration is unquestionably more efficient at rapidly increasing blood concentrations of the substance concerned. However, infusions are not always the method of choice, so scientists and researchers need to find alternatives that are both appropriate and practical. A promising solution now appears to have been found: liposomal absorption technology.
Starting with the basics: what are liposomes?
Liposomes were first discovered by Dr Alec Bangham in 1961 and described in his 1964 publication. He observed that dispersing, or mixing, lecithin and water produced spherical structures with multiple layers. This observation reflects a natural phenomenon: under certain conditions, lipids form bubbles that enclose liquids. This creates an emulsion of two components that do not mix. The lipid bubbles consist of lipid bilayers and provide a biocompatible transport system for active substances or nutrients. They are used mainly in medicines and less often in food supplements.
Liposomes are therefore spherical sacs, known as vesicles, made up of one or more lipid bilayer membranes. They consist of the same material as our own natural cell membranes and enclose an aqueous core. Their structure allows them to encapsulate and transport both water-soluble and fat-soluble substances. These and other properties have been used primarily in clinical medicine since 1995 to administer medicines, with chemotherapy among the first applications.

A closer look at lipids
Lipids comprise fats and fat-like substances. They are hydrophobic, meaning that they dissolve poorly, if at all, in water but much more readily in solvents such as alcohol.
Lipids occur in all our body cells as components of biological membranes. These membranes consist of lipid bilayers in which two lipid molecules face each other. Their hydrophobic, or water-repellent, parts face one another in the centre of the membrane, while their hydrophilic, or water-attracting, parts face outwards. Important components of the lipids in our cell membranes include omega-3 fatty acids, particularly DHA, which is found, for example, in our Algenkraft and Krill-Öl products.
Production and applications

The membranes of conventional liposomes consist of phospholipids. The raw materials used may be of natural or synthetic origin. As the composition of lipids from natural sources varies considerably and is difficult to control, manufacturers generally use less expensive synthetic alternatives. Different additives and processes can then be used to alter the structure and properties of the liposomes.
Liposomes can enable the body to absorb both water-soluble and fat-soluble molecules effectively. Because the liposome membrane resembles our own cell membranes, a liposome can fuse with cells and release its contents directly inside them.
Liposomes with a bilayer membrane made solely of phospholipids have proved relatively unstable and inefficient because they interact with proteins circulating in the blood, which affects their absorption and action. More recent approaches therefore aim to modify this lipid bilayer, for example to extend circulation time, increase elasticity and bioavailability, or direct delivery to specific cells, known as drug targeting. This involves altering the composition, size and charge of the liposomes. So far, however, these techniques have not satisfactorily met expectations. Adjusting physicochemical properties to optimise liposomes for particular tissues and applications has proved especially difficult.
How useful are liposomal nutrient supplements?
Microencapsulating nutrients in liposomes offers the advantage of high bioavailability for both fat-soluble and water-soluble substances. Their compatibility with our own body cells enables rapid absorption and high blood concentrations of the active substance within a short time.
How well the body absorbs a particular nutrient depends on several factors, including molecular size, dose and molecular composition. It is particularly important to emphasise that carefully matching the liposomal active substance to its intended use and determining its dose are essential to maximise the therapeutic benefit.
In principle, the benefit of liposomal encapsulation should be assessed individually for each active substance and its therapeutic aim. Not every nutrient has inherently low bioavailability, so the added benefit of taking it in liposomal form may be questionable.
Despite their clinical relevance and therapeutic potential, the possible disadvantages associated with administering liposomes are not yet sufficiently understood. These include their toxicological assessment and interactions with the immune system observed in some studies. Such studies described inflammatory responses characterised by the release of pro-inflammatory signalling substances.
Liposomes are also sensitive structures and may be unstable for various reasons. They have a considerably shorter shelf life than conventional food supplements. Few manufacturers produce high-quality liposomes with a long shelf life. For economic reasons, liquid liposomal formulations are generally used in food supplements. However, if they remain unstabilised in a solution, they aggregate and clump together, negating the effect. Ethanol or potassium sorbate is therefore usually added as a stabiliser. The latter is a chemically synthesised preservative. Liposomal powders are more expensive and demanding to manufacture, and can be kept stable only by freeze-drying. This makes them less practical for everyday use. The possibility of an overdose and associated side effects cannot be entirely ruled out either.
There is no general answer to how much nutrient availability can be increased; this varies from one nutrient to another. Liposomes are particularly suited to nutrients with naturally low bioavailability that cannot, or can barely, be improved by other means. To realise the full potential of liposome-based systems for delivering nutrients and active substances, the mechanisms through which liposomes interact with our bodies, especially the immune system, should continue to be investigated systematically and understood.
Important milestones over the past two decades have advanced liposome technology considerably. Nevertheless, further work is needed to optimise the properties, characteristics and efficiency of liposomal encapsulation. Although liposomal delivery is often promoted as the ultimate solution, in our view the overall evidence remains insufficient to assess the benefits and, in particular, the potential side effects of the technology. Naturalness is another aspect to consider: nutrients packaged in liposomes do not occur in this form in nature and must first be produced using specialised processes. Even so, liposomal absorption technology is a fascinating and promising field of research, and we look forward to future findings.
Sources and references
- Glukhova OE (2020): Liposome Drug Delivery System across Endothelial Plasma Membrane: Role of Distance between Endothelial Cells and Blood Flow Rate. Molecules 2020, 25(8), 1875.
- Zylberberg C, Matosevic S (2016): Pharmaceutical liposomal drug delivery: a review of new delivery systems and a look at the regulatory landscape. Drug Deliv. 2016 Nov;23(9):3319-3329.
- Inglut CT et al. (2020): Immunological and Toxicological Considerations for the Design of Liposomes. Nanomaterials (Basel). 2020 Feb; 10(2): 190.
- Abu Lila AS, Ishida T (2016): Liposomal Delivery Systems: Design Optimization and Current Applications. Biol. Pharm. Bull. 40: (1), 1–10.
- Misra A et al. (2009): Recent Advances in Liposomal Dry Powder Formulations: Preparation and Evaluation. Expert Open Drug Deliv. 2009 Jan;6(1): 71-89.
- Yu LX, Li BV (2014): FDA Bioequivalence Standards. Springer: New York, Heidelberg, Dordrecht, London.
- U. S. Food and Drug Administration (2018): Liposome Drug Products. Chemistry, Manufacturing, and Controls; Human Pharmacokinetics and Bioavailability; and Labeling Documentation. Guidance for Industry.
- Triebel HD (2011): Kompakt-Wissen Biologie. Stark Verlagsgesellschaft mbH & Co. KG. 2. Auflage.



